文献速递糖尿病

度拉糖肽在老年患者中的疗效与安全性:REWIND试验事后分析

Efficacy and Safety of Dulaglutide in Older Patients: A post hoc Analysis of the REWIND trial.
PubMed 文献 · J Clin Endocrinol Metab · 2021-01-01

REWIND试验事后分析按年龄(≥65岁与<65岁)比较度拉糖肽与安慰剂的效果。≥65岁患者5256例(平均71.0岁),<65岁4645例(平均60.7岁)。度拉糖肽在两组中降低MACE发生率相似(11% vs 13%),安全性事件无显著差异。

要点

  • 度拉糖肽在≥65岁与<65岁患者中降低MACE效果相似。
  • 永久停药、全因死亡、心衰住院等安全性事件两组相似。
  • 严重心脏传导障碍发生率数值上度拉糖肽组较高但无统计学差异。

核心结论

  • 度拉糖肽在≥65岁和<65岁患者中疗效与安全性相似。

研究设计与样本

  • REWIND试验事后亚组分析,在24国371个中心进行。
  • 纳入50岁及以上2型糖尿病合并心血管疾病或多种心血管危险因素患者。
  • 随机1:1接受度拉糖肽1.5 mg或安慰剂,作为当地标准治疗的附加治疗。
  • ≥65岁患者5256例(平均71.0岁),<65岁患者4645例(平均60.7岁)。

主要发现

  • 度拉糖肽治疗在老年与年轻患者中MACE发生率降低相似(11% vs 13%)。
  • 每个年龄亚组内,永久停药、全因死亡、心衰住院、严重低血糖、严重肾脏或泌尿事件及严重胃肠道事件发生率在治疗组间相似。
  • 每个年龄亚组内,度拉糖肽组严重心脏传导障碍发生率数值上高于安慰剂组,但差异无统计学意义。

临床怎么用

  • 对于≥65岁的2型糖尿病合并心血管疾病或高危患者,度拉糖肽的疗效与安全性与年轻患者相似。

局限性

  • 为事后亚组分析,结果需谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Dulaglutide reduced major adverse cardiovascular events (MACE) in the Researching Cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial. Its efficacy and safety in older vs younger patients have not been explicitly analyzed. OBJECTIVE: This work aimed to assess efficacy and safety of dulaglutide vs placebo in REWIND by age subgroups (≥ 65 and < 65 years). METHODS: A post hoc subgroup analysis of REWIND was conducted at 371 sites in 24 countries. Participants included type 2 diabetes patients aged 50 years or older with established cardiovascular (CV) disease or multiple CV risk factors, and a wide range of glycemic control. Patients were randomly assigned (1:1) to dulaglutide 1.5 mg or placebo as an add-on to country-specific standard of care. Main outcomes measures included MACE (first occurrence of the composite of nonfatal myocardial infarction, nonfatal stroke, or death from CV or unknown causes). RESULTS: There were 5256 randomly assigned patients who were 65 years or older (mean = 71.0), and 4645 were younger than 65 years (mean = 60.7). Baseline characteristics were similar in randomized treatment groups. Dulaglutide treatment showed a similar reduction in the incidence (11% vs 13%) of MACE in older vs younger patients. The rate of permanent study drug discontinuation, incidence of all-cause mortality, hospitalizations for heart failure, severe hypoglycemia, severe renal or urinary events, and serious gastrointestinal events were similar between randomized treatment groups within each age subgroup. The incidence rate of serious cardiac conduction disorders was numerically higher in the dulaglutide group compared to placebo within each age subgroup but the difference was not statistically significant. CONCLUSION: Dulaglutide had similar efficacy and safety in REWIND in patients65 years and older and those younger than 65 years.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Riddle MC, Gerstein HC, Xavier D, et al. Efficacy and Safety of Dulaglutide in Older Patients: A post hoc Analysis of the REWIND trial. J Clin Endocrinol Metab. 2021. PMID: 33537745. doi:10.1210/clinem/dgab065

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。